The University of Tokyo is set to launch a new clinical trial using nafamostat, a blood thinner and enzyme inhibitor used to treat pancreatic and kidney disease that has been identified as a potential treatment for COVID-19. The hypothesis: the drug’s mechanism could...
Tokyo Medical and Dental University (TMDU), ACT Genomics (Taipei, Taiwan) and ACTmed (Japan) jointly launched a clinical research collaboration targeting the establishment of comprehensive genomic profiles of high prevalent cancers afflicting the Japanese...
A University of Tokyo clinical investigation team will commence the nation’s first clinical trial centering on a vaccine for the Ebola virus. Professor Yoshihiro Kawaoka and colleagues from the Institute of Medical Science at the prestigious Japanese institution,...
South Korean biopharma companies, such as Chong Kun Dang and Dong-A ST, move to launch biosimilars in Japan despite some trade tensions, as their therapies will be managed and distributed by Japanese firms. For example, both firms have applied for their respective...
Tokyo, Japan-based M3 Inc. is a network of physicians worldwide. With 250,000 members in Japan and 3.5 million worldwide in the USA, UK, China, Korea and India, they provide a treasure trove for research access (investigators),health information and career...
Iqra Farooq with AML Global Portal writes the prognosis of younger patients with acute myeloid leukemia (AML) has improved with the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and advanced supportive care. But, in most elderly...
